Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    "methodist hospital" | Open Studies | "Leukemia, Lymphocytic, Chronic, B-Cell" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
Interventions: Biological: CD19 CAR T Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
2 Recruiting Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Conditions: Lymphoma;   Myeloma;   Leukemia
Intervention: Biological: Kappa CD28 T cells
3 Recruiting Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Conditions: Non-Hodgkin's Lymphoma;   B-Cell ALL;   B-Cell CLL
Interventions: Genetic: CD19.CAR-CD28Z T Cells - dose escalation 2;   Genetic: CD19.CAR-CD28Z T Cells - dose escalation 1
4 Recruiting Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Conditions: Acute Undifferentiated Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies;   Childhood Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hairy Cell Leukemia;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Neoplasm of Uncertain Malignant Potential;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure

Study has passed its completion date and status has not been verified in more than two years.